Comparative Pharmacology
Head-to-head clinical analysis: AXUMIN versus RADIOGENIX SYSTEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXUMIN versus RADIOGENIX SYSTEM.
AXUMIN vs RADIOGENIX SYSTEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor; inhibits VEGFR-1, -2, -3, and PDGFR-β, Kit, and RET.
RADIOGENIX SYSTEM is a radiopharmaceutical that emits beta radiation (yttrium-90 microspheres) to deliver targeted radiotherapy to hepatic tumors via intra-arterial administration, causing irreversible DNA damage and cell death.
AXUMIN (florbetaben F 18) is a diagnostic radiopharmaceutical for PET imaging of beta-amyloid plaques. The recommended dose is 300 MBq (8.1 mCi) administered as a single intravenous bolus injection over 10-15 seconds, followed by a saline flush.
Not applicable; the RADIOGENIX SYSTEM is a medical imaging device, not a pharmacologic agent. No standard dosing.
None Documented
None Documented
The terminal elimination half-life is approximately 2.7 hours (range 1.5-5.0 hours) in patients with normal renal function; this supports twice-daily dosing, but may be prolonged in renal impairment.
Physical half-life of 6.0 hours for Tc-99m; effective half-life is approximately 6.0 hours due to rapid renal clearance.
Renal elimination of unchanged drug accounts for approximately 60% of the administered dose; fecal excretion accounts for approximately 35% (mainly as unchanged drug); biliary excretion contributes to fecal elimination; less than 1% is excreted in urine as metabolites.
Primarily renal excretion; >95% of administered activity excreted in urine within 24 hours; negligible biliary or fecal elimination.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical